Cargando…

Cost analysis of adverse events associated with non-small cell lung cancer management in France

BACKGROUND: Adverse events (AEs) related to medical treatments in non-small cell lung cancer (NSCLC) are frequent and need an appropriate costing in health economic models. Nevertheless, data on costs associated with AEs in NSCLC are scarce, particularly since the development of immunotherapy with s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chouaid, Christos, Loirat, Delphine, Clay, Emilie, Millier, Aurélie, Godard, Chloé, Fannan, Amira, Lévy-Bachelot, Laurie, Angevin, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538537/ https://www.ncbi.nlm.nih.gov/pubmed/28794648 http://dx.doi.org/10.2147/CEOR.S138963

Ejemplares similares

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
por: Bowrin, Kevin, et al.
Publicado: (2020)

Current process and future path for health economic assessment of pharmaceuticals in France
por: Toumi, Mondher, et al.
Publicado: (2015)

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment
por: Toumi, Mondher, et al.
Publicado: (2017)

Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis
por: Charbonnel, Bernard, et al.
Publicado: (2017)

Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France
por: Atsou, Kokuvi, et al.
Publicado: (2016)

A prospective study of health care resource utilisation and selected costs of schizophrenia in France
por: Sarlon, Emmanuelle, et al.
Publicado: (2012)

Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France
por: Pignata, Maud, et al.
Publicado: (2017)

Determinants of orphan drugs prices in France: a regression analysis
por: Korchagina, Daria, et al.
Publicado: (2017)

The association between asthma control, health care costs, and quality of life in France and Spain
por: Doz, Marianne, et al.
Publicado: (2013)

Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France
por: Maunoury, Franck, et al.
Publicado: (2018)

A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France
por: Taipale, Kaisa, et al.
Publicado: (2017)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
por: Bowrin, Kevin, et al.
Publicado: (2020)

Health related quality of life in patients having schizophrenia negative symptoms – a systematic review
por: Azaiez, Chiraz, et al.
Publicado: (2018)

Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
por: Guelfucci, Florent, et al.
Publicado: (2013)

Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France
por: Clay, Emilie, et al.
Publicado: (2019)

Método de Francés : Segundo libro para enseñanza Secundaria, Comercial ó Preparatoria
por: Godard Charles
Publicado: (1936)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
por: Zhou, Junwen, et al.
Publicado: (2019)

Factors associated with excessively lengthy treatment of tuberculosis in the eastern Paris region of France in 2004
por: Valin, Nadia, et al.
Publicado: (2010)

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
por: Jaspard, Marie, et al.
Publicado: (2020)

Simulation-Based Estimates of Effectiveness and Cost-Effectiveness of Smoking Cessation in Patients with Chronic Obstructive Pulmonary Disease
por: Atsou, Kokuvi, et al.
Publicado: (2011)

Analysis of COVID-19 inpatients in France during first lockdown of 2020 using explainability methods
por: Excoffier, Jean-Baptiste, et al.
Publicado: (2022)

Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland
por: Soini, Erkki, et al.
Publicado: (2020)

Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database
por: Emery, Corinne, et al.
Publicado: (2020)

Hospital admissions and mortality for acute exacerbations of COPD during the COVID-19 pandemic: A nationwide study in France
por: Poucineau, Jonas, et al.
Publicado: (2022)

Direct medical costs of adverse events in Dutch hospitals
por: Hoonhout, Lilian HF, et al.
Publicado: (2009)

Assessment of costs associated with adverse events in patients with cancer
por: Wong, William, et al.
Publicado: (2018)

Costs associated with adverse events among acute patients
por: Kjellberg, Jakob, et al.
Publicado: (2017)

Cross-sectional study on comorbidities and adverse events in patients with advanced and recurrent ovarian cancer in France
por: Le Saux, Olivia, et al.
Publicado: (2015)

Patient-reported tolerability of adverse events in phase 1 trials
por: Henon, Clémence, et al.
Publicado: (2017)

Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis
por: Chouaid, Christos, et al.
Publicado: (2018)

Risk factors for early mortality of lung cancer patients in France: A nationwide analysis
por: Goussault, Hélène, et al.
Publicado: (2022)

Gestational diabetes and adverse perinatal outcomes from 716,152 births in France in 2012
por: Billionnet, Cécile, et al.
Publicado: (2017)

Genomic features of Mycoplasma bovis subtypes currently circulating in France
por: Ambroset, Chloé, et al.
Publicado: (2022)

Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents
por: Vergnenègre, A, et al.
Publicado: (2013)

Targeted therapy for localized non-small-cell lung cancer: a review
por: Paleiron, Nicolas, et al.
Publicado: (2016)

Hospital costs associated with adverse events in people with diabetes in the UK
por: Keng, Mi Jun, et al.
Publicado: (2022)

Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain
por: Kearns, Benjamin, et al.
Publicado: (2021)

Evaluation of the Direct Costs of Managing Adverse Drug Events in all Ages and of Avoidable Adverse Drug Events in Older Adults in Japan
por: Katsuno, Hayato, et al.
Publicado: (2021)

EPH4 Burden and Characteristics of COVID-19 in France During 2020 Based on National Hospital Database
por: Leboucher, C, et al.
Publicado: (2022)

Economic Impact of a triptan Rx-To-OTC Switch in Six EU Countries
por: Millier, Aurelie, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_t9tm7heru74d3qeu6da7p5mhib